Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.

NCT05203003 · clinicaltrials.gov ↗
RECRUITING
Status
260
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Assistance Publique - Hôpitaux de Paris